Byoung‐Gie Kim

Samsung Medical Center — South Korea

Medicine · Health Sciences

58h-index17.3kcitations551works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(229), Endometrial and Cervical Cancer Treatments(158), Uterine Myomas and Treatments(66), PARP inhibition in cancer therapy(65), Cervical Cancer and HPV Research(62)

Publications542 total

Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study
Gynecologic Oncology·2025
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Risk Factors Affecting Clinical Outcomes of Low-risk Early-stage Human Papillomavirus–Associated Endocervical Adenocarcinoma Treated by Surgery Alone: Application of Silva Pattern
International Journal of Gynecological Pathology·2025
Impact of tremelimumab dosing and sequence on tumor immune microenvironment and efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: Insights from the TRU-D/KGOG-3046 study
Gynecologic Oncology·2025
Improved Prognostic Stratification with the FIGO 2023 Staging System in Endometrial Cancer: Real-World Validation in 2969 Patients
Cancers·2025Open Access
Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study
Gynecologic Oncology·2025· 1 cited
Surgery plus post-operative radiotherapy versus definitive chemoradiotherapy in locally advanced endocervical adenocarcinoma
International Journal of Gynecological Cancer·2025
The decision for adjuvant therapy for early-stage high-risk endometrial cancer is in dilemma
Taiwanese Journal of Obstetrics and Gynecology·2025· 5 citedOpen Access
LLMail-Inject: A Dataset from a Realistic Adaptive Prompt Injection Challenge
arXiv (Cornell University)·2025Open Access
Biomarker results from the KGOG3056/NIRVANA-R trial: Maintenance niraparib plus bevacizumab in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
Journal of Clinical Oncology·2025
E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).
Journal of Clinical Oncology·2025
Data from Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial
2025Open Access
page 1 of 28Next →

Frequent Co-authors

Duk‐Soo Bae(33), Tae‐Joong Kim(24), Chel Hun Choi(21), Jeong‐Won Lee(15), Yoo-Young Lee(15), Jeong‐Won Lee(15), Je–Ho Lee(12), Sang Yong Song(7), Nicoletta Colombo(6), Giovanni Scambia(6), Paul DiSilvestro(6), Jung‐Joo Choi(6), Ana Oaknin(5), Michael Friedländer(5), Anne Floquet(5), Susana Banerjee(5), Amit M. Oza(5), Keiichi Fujiwara(5), Taejong Song(5), Kathleen N. Moore(4)